Veracyte, Inc. (VCYT)
NASDAQ: VCYT · Real-Time Price · USD
42.55
+0.27 (0.64%)
Dec 31, 2025, 1:28 PM EST - Market open
Veracyte Revenue
Veracyte had revenue of $131.87M in the quarter ending September 30, 2025, with 13.82% growth. This brings the company's revenue in the last twelve months to $495.14M, up 16.41% year-over-year. In the year 2024, Veracyte had annual revenue of $445.76M with 23.46% growth.
Revenue (ttm)
$495.14M
Revenue Growth
+16.41%
P/S Ratio
6.68
Revenue / Employee
$600,899
Employees
824
Market Cap
3.36B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 445.76M | 84.71M | 23.46% |
| Dec 31, 2023 | 361.05M | 64.52M | 21.76% |
| Dec 31, 2022 | 296.54M | 77.02M | 35.09% |
| Dec 31, 2021 | 219.51M | 102.03M | 86.85% |
| Dec 31, 2020 | 117.48M | -2.89M | -2.40% |
| Dec 31, 2019 | 120.37M | 28.36M | 30.82% |
| Dec 31, 2018 | 92.01M | 20.06M | 27.87% |
| Dec 31, 2017 | 71.95M | 6.87M | 10.55% |
| Dec 31, 2016 | 65.09M | 15.58M | 31.48% |
| Dec 31, 2015 | 49.50M | 11.31M | 29.62% |
| Dec 31, 2014 | 38.19M | 16.31M | 74.51% |
| Dec 31, 2013 | 21.88M | 10.26M | 88.20% |
| Dec 31, 2012 | 11.63M | 8.98M | 339.62% |
| Dec 31, 2011 | 2.65M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
VCYT News
- 1 day ago - Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 7 weeks ago - Veracyte to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Veracyte, Inc. (VCYT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Veracyte Announces Third Quarter 2025 Financial Results - Business Wire
- 2 months ago - Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing - Business Wire
- 2 months ago - Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025 - Business Wire
- 3 months ago - Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer - Business Wire
- 3 months ago - Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025 - Business Wire